Acquisition of InVivo by BRUKER

InVivo starts this year with big news!

We are pleased to announce today that BRUKER has acquired InVivo BioTech Services to expand their Molecular Biology, Microbiology and Pathology Consumables and Assay Business. As a part of BRUKER Daltonics, InVivo will continue to serve you with their well-known outstanding level of quality and service. InVivo will operate under its existing name and management team, and is looking forward to expanding its business with interesting projects.






Dr. Wolfgang Weglöhner and Mr. Siegmund Karasch, the founders and Managing Directors of InVivo BioTech, commented: “We are very pleased by the expanded opportunities for our business using the global commercial infrastructure of Bruker, particularly for microbiology and pathology.  With our molecular biology core products and CMO services, we anticipate significant growth and expansion opportunities.”

InVivo welcomes Dr. Nils Morgenthaler. He will complete the Managing Directors team of InVivo BioTech.

Click here for the official press release.

InVivo BioTech Services is growing


With merger of ICI into InVivo, InVivo has a new operating facility in Berlin and is able to expand their service portfolio by immunoassay development and sample analysis.

We proudly present our new website!


InVivo invested several years into research to achieve the best results in transient gene expression. We expressed a variety of proteins for target discovery and accomplished production sizes of up to 2 g for preclinical studies. To accomplish such ground-breaking results we optimized different factors, which influence the yield of recombinant proteins. A lot of customers already profit from our expertise, but now we want to share our knowledge with all interested scientists. For this reason we released a new website, with insights into our work and experience. We´d like to invite you to visit our website.